BIOKE and Fluidigm Announce Exclusive Distribution Agreement
News Aug 06, 2007
The Fluidigm says that the BioMark system provides orders-of-magnitude increase in throughput compared to conventional RT-PCR and genotyping platforms, at a fraction of the labor and running cost. This breakthrough is possible because the BioMark system reads dynamic arrays – nanofluidic chips that contain preprogrammed fluidic networks that automatically combine sets of samples with sets of PCR assays.
BioMark dynamic arrays can provide a high-throughput and means to validate gene- or SNP-based biomarkers by PCR. An array generates 2,304 PCR assays, yet it requires only 96 pipetting steps (input of 48 off-the-shelf primer-probe sets and 48 samples), or 1/40 the pipetting steps required by 384-well systems.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.